A long-term follow-up of serum myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with graves disease treated with propylthiouracil

Endocrine Journal

Volumn 57, Issue 1, 2010, Pages 73-79

  Ishii, Reiko ^a   Imaizumi, Misa ^a,b   Ide, Akane ^a   Sera, Nobuko ^b   Ueki, Ikuko ^a   Horie, Ichiro ^a   Ando, Takao ^a   Usa, Toshiro ^a   Ejima, Eri ^c   Ashizawa, Kiyoto ^d   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^c National Saga Hospital   (Japan)

^d Nagasakiken Saiseikai Hospital   (Japan)

Author keywords

Graves disease; MPO ANCA; Propylthiouracil

Indexed keywords

MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; LONG TERM CARE; MALE; SEX DIFFERENCE; TREATMENT WITHDRAWAL; VASCULITIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTITHYROID AGENTS; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; PROPYLTHIOURACIL; STATISTICS, NONPARAMETRIC;

EID: 76049087362     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K09E-230     Document Type: Article

References (21)

1. Hoffman, G.S. & Specks, U. (1998) Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41, 1521-1537.
2. Stankus, S.J. & Johnson, N.T. (1992) Propylthiouracilinduced hypersensitivity vasculitis presenting as respiratory failure. Chest 102, 1595-1596.
3. Ashizawa, K. & Eguchi, K. (2003) Serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease receiving anti-thyroid medication. Intern Med 42, 463-464.
4. Sera, N., Ashizawa, K., Ando, T., Abe, Y., Ide, A., Usa, T., Tominaga, T., Ejima, E., Yokoyama, N. & Eguchi, K. (2000) Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 10, 595-599.
5. Sato, H., Hattori, M., Fujieda, M., Sugihara, S., Inomata, H., Hoshi, M. & Miyamoto, S. (2000) High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 85, 4270-4273.
6. Gunton, J.E., Stiel, J., Clifton-Bligh, P., Wilmshurst, E. & Mcelduff, A. (2000) Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 142, 587.
7. Noh, J.Y., Asari, T., Hamada, N., Makino, F., Ishikawa, N., Abe, Y., Ito, K. & Ito, K. (2001) Frequency of appearance of myeloperoxidase- antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (oxf) 54, 651-654.
8. Wada, N., Mukai, M., Kohno, M., Notoya, A., Ito, T. & Yoshioka, N. (2002) Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 49, 329-334.
9. Bonaci-Nikolic, B., Nikolic, M.M., Andrejevic, S., Zoric, S. & Bukilica, M. (2005) Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 7, R1072-1081.
10. Yazisiz, V., Ongut, G., Terzioglu, E. & Karayalcin, U. (2008) Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract, doi: 10.1111/j.1742-1241 .2007.01485.x
11. Cin, M.O., Gursoy, A., Morris, Y., Aydintug, O.T., Kamel, N. & Gullu, S. (2009) Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. Int J Clin Pract 63, 299-302.
12. Sera, N., Yokoyama, N., Abe, Y., Ide, A., Usa, T., Tominaga, T., Ejima, E., Kawakami, A., Ashizawa, K. & Eguchi, K. (2000) Antineutrophil cytoplasmic antibody-associated vasculitis complicating Graves' desease: Report of two adult cases. Acta Med. Nagasaki 45, 33-36.
13. Poomthavorn, P., Mahachoklertwattana, P., Tapaneya-Olarn, W., Chuansumrit, A. & Chunharas, A. (2002) Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease. J Med Assoc Thai 85 Suppl 4, S1295-1301.
14. Gao, Y., Chen, M., Ye, H., Guo, X.H., Zhao, M.H. & Wang, H.Y. (2007) Follow-up of avidity and titre of anti-myeloperoxidase antibodies in sera from pa tients with propylthiouracil-induced vasculitis. Clin Endocrinol (oxf) 66, 543-547.
15. Harper, L., Chin, L., Daykin, J., Allahabadia, A., Heward, J., Gough, S.C., Savage, C.O. & Franklyn, J.A. (2004) Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease. Clin Endocrinol (oxf) 60, 671-675.
16. Lam, D.C. & Lindsay, R.H. (1979) Accumulation of 2-[14c] propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 28, 2289-2296.
17. Lee, E., Hirouchi, M., Hosokawa, M., Sayo, H., Kohno, M. & kariya, K. (1988) Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 37, 2151-2153.
18. Williams, J.M., Kamesh, L. & Savage, C.O. (2005) Translating basic science into patient therapy for ANCA-associated small vessel vasculitis. Clin Sci (Lond) 108, 101-112.
19. Ye, H., Gao, Y., Guo, X.H. & Zhao, M.H. (2005) Titre and affinity of propylthiouracil-induced anti-myeloperoxidase antibodies are closely associated with the development of clinical vasculitis. Clin Exp Immunol 142, 116-119.
20. Noh, J.Y., Yasuda, S., Sato, S., Matsumoto, M., Kunii, Y., Noguchi, Y., Mukasa, K., Ito, K., Ito, K., Sugiyama, O., Kobayashi, H., Nihojima, S., Okazaki, M. & Yokoyama, S. (2009) Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab 94, 2806-2811.
21. Jennette, J.C., Xiao, H. & Falk, R.J. (2006) Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 17, 1235-1242.